

# Marta Castiglia

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5410633/marta-castiglia-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32  
papers

772  
citations

17  
h-index

27  
g-index

33  
ext. papers

911  
ext. citations

4.2  
avg, IF

3.65  
L-index

#	Paper	IF	Citations
32	Liquid biopsies in lung cancer: the new ambrosia of researchers. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2014</b> , 1846, 539-46	11.2	95
31	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. <i>Oncotarget</i> , <b>2016</b> , 7, 60712-60722	3.3	79
30	Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?. <i>Analytical Cellular Pathology</i> , <b>2015</b> , 2015, 690916	3.4	61
29	Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 89, 300-13	7	56
28	The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. <i>Scientific Reports</i> , <b>2018</b> , 8, 13379	4.9	48
27	Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer. <i>Advances in Experimental Medicine and Biology</i> , <b>2016</b> , 937, 207-28	3.6	43
26	Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) PatientsVPlasma Through qPCR: A Feasible Liquid Biopsy Tool. <i>Journal of Visualized Experiments</i> , <b>2016</b> ,	1.6	38
25	ALK and crizotinib: after the honeymoon what else? Resistance mechanisms and new therapies to overcome it. <i>Translational Lung Cancer Research</i> , <b>2014</b> , 3, 250-61	4.4	37
24	Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients. <i>Therapeutic Advances in Medical Oncology</i> , <b>2019</b> , 11, 1758835919839928	5.4	29
23	Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. <i>Oncotarget</i> , <b>2016</b> , 7, 47821-47830	3.3	28
22	Hypoxia and human genome stability: downregulation of BRCA2 expression in breast cancer cell lines. <i>BioMed Research International</i> , <b>2013</b> , 2013, 746858	3	24
21	Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis. <i>Current Cancer Drug Targets</i> , <b>2018</b> , 18, 697-705	2.8	23
20	Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920942378	5.4	22
19	Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?. <i>Oncotarget</i> , <b>2016</b> , 7, 29321-32	3.3	21
18	Dietary restriction: could it be considered as speed bump on tumor progression road?. <i>Tumor Biology</i> , <b>2016</b> , 37, 7109-18	2.9	21
17	EGFR inhibition in NSCLC: New findings and opened questions?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 112, 126-135	7	20
16	Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , <b>2019</b> , 11, 1758835919874653	5.4	18

15	Nintedanib in NSCLC: evidence to date and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , <b>2016</b> , 8, 188-97	5.4	17
14	A headlight on liquid biopsies: a challenging tool for breast cancer management. <i>Tumor Biology</i> , <b>2016</b> , 37, 4263-73	2.9	17
13	Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in Genes. <i>Cancers</i> , <b>2020</b> , 12,	6.6	14
12	Spheroids from adipose-derived stem cells exhibit an miRNA profile of highly undifferentiated cells. <i>Journal of Cellular Physiology</i> , <b>2018</b> , 233, 8778-8789	7	14
11	Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma. <i>Journal of Molecular Pathology</i> , <b>2021</b> , 2, 173-196	0.4	10
10	Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
9	Adipose tissue, angiogenesis and angio-MIR under physiological and pathological conditions. <i>European Journal of Cell Biology</i> , <b>2019</b> , 98, 53-64	6.1	7
8	An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. <i>Expert Opinion on Drug Safety</i> , <b>2019</b> , 18, 485-496	4.1	6
7	TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study. <i>Journal of Clinical Pathology</i> , <b>2021</b> ,	3.9	4
6	Cell quality evaluation with gene expression analysis of spheroids (3D) and adherent (2D) adipose stem cells. <i>Gene</i> , <b>2021</b> , 768, 145269	3.8	4
5	Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211018018	5.4	4
4	Cell-free DNA and exoDNA analysis in metastatic colorectal cancer patients (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e16093-e16093	2.2	0
3	Not all 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs). <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211049779	5.4	0
2	Targeted Therapy. <i>UNIPA Springer Series</i> , <b>2021</b> , 181-206	0.1	
1	KRAS and BRAF as prognostic biomarkers in patients undergoing surgical resection of colorectal cancer liver metastasis: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3565-3565	2.2	